As of March 31, 2024, Zevra Therapeutics' Cash, Cash Equivalents, And Investments Were $52.7M, April 5, 2024, The Company Announced Refinancing Of Existing Debt With Up To $100M In Committed Capital, Expected To Provide Cash Runway Into 2026

5/8/24 7:32:10 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ZVRA alert in real time by email

Get the next $ZVRA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ZVRA

Date	Price Target	Rating	Analyst
10/7/2024	$20.00	Buy	Guggenheim
9/24/2024	$17.00	Mkt Outperform	JMP Securities
9/24/2024	$18.00 → $25.00	Buy	Maxim Group
4/2/2024	$12.00 → $18.00	Buy	Maxim Group
3/12/2024		Outperform	William Blair
3/17/2023	$12.00	Buy	Maxim Group

More analyst ratings

$ZVRA
Press Releases

Fastest customizable press release news feed in the world

Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024
CELEBRATION, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases, today announced it will report third quarter financial results and provide a corporate update on Tuesday, Nov. 12, 2024. The Company will issue a news release after the market closes and host a conference call/audio webcast at 4:30 p.m. ET that day. The corporate update will include recent progress with the commercial launches of MIPLYFFA™ and OLPRUVA® as well as the Company's clinical stage programs. A link to the audio webcast will be accessible on the "Events & Presentations"
10/31/24 7:30:00 AM ET
$ZVRA
Biotechnology: Pharmaceutical Preparations
Health Care
Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
CELEBRATION, Fla., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane, President and Chief Executive Office of Zevra, will participate in a Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, presented by Maxim Group LLC on Thursday, October 17, 2024 at 2 p.m. ET. Maxim Group 2024 Annual Healthcare Conference Rare Disease Panel on Thursday, October 17, 2024, at 2:00 p.m. ET. This conference will be live on M-Vest. To attend, investors can register and watch the company discussion on the M-Vest page. The archived presentation will also be accessible und
10/10/24 7:30:00 AM ET
$ZVRA
Biotechnology: Pharmaceutical Preparations
Health Care
NUCDF and Zevra Therapeutics Launch Check Ammonia Campaign to Highlight Critical Importance of Prompt, Accurate Blood Ammonia Testing for Diagnosing Urea Cycle Disorders
PASADENA, Calif. and CELEBRATION, Fla., Oct. 09, 2024 (GLOBE NEWSWIRE) -- The National Urea Cycle Disorders Foundation (NUCDF) and Zevra Therapeutics, Inc. (NASDAQ:ZVRA) are teaming up to launch an awareness campaign during the month of October to improve the diagnosis of urea cycle disorders (UCDs). Their goal is to highlight the critical importance of promptly checking blood ammonia levels and using proper testing techniques. A blood ammonia test is essential to uncover elevated ammonia levels (hyperammonemia), the classic sign of a urea cycle disorder. Resources on recognizing and testing for hyperammonemia are featured on the campaign website, checkammonia.com. Quickly diagnosing UCD
10/9/24 9:00:00 AM ET
$ZVRA
Biotechnology: Pharmaceutical Preparations
Health Care

$ZVRA
Market Insights

Live Market Insights

10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. Here's the list of options activity happening in today's session: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume BSX PUT SWEEP BEARISH 08/16/24 $75.00 $68.9K 5.5K 2.1K MRNA CALL SWEEP NEUTRAL 11/15/24 $170.00 $121.
7/23/24 1:35:23 PM ET
$ALGN
$BSX
$DHR
$EVH
Industrial Specialties
Health Care
Medical/Dental Instruments
Industrial Machinery/Components
Insiders Buying Zevra Therapeutics And 1 Other Stock
Although U.S. stocks closed mixed on Wednesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company’s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga’s insider transactions platform. Zevra Therapeutics The Trade: Zevra Therapeutics, Inc. (NASDAQ:ZVRA) CFO & Treasurer R. Laduane Clifton acquired a total o
7/18/24 6:58:20 AM ET
$CTRN
$ZVRA
Clothing/Shoe/Accessory Stores
Consumer Discretionary
Biotechnology: Pharmaceutical Preparations
Health Care
Insiders Buying Barnes & Noble Education And 2 Other Stocks
Although U.S. stocks closed higher on Tuesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company’s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga’s insider transactions platform. Barnes & Noble Education The Trade: Barnes & Noble Education, Inc. (NYSE:BNED) Director Eric Singer acquired a total of 18,
7/17/24 9:08:14 AM ET
$BNED
$CULP
$ZVRA
Other Specialty Stores
Consumer Discretionary
Textiles
Biotechnology: Pharmaceutical Preparations

$ZVRA
Leadership Updates

Live Leadership Updates

Zevra Therapeutics Expands Executive Leadership Team
Rahsaan W. Thompson appointed as Chief Legal Officer, Secretary and Compliance Officer Alison Peters appointed as Chief People Officer CELEBRATION, Fla., June 25, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced the appointments of Rahsaan W. Thompson as Chief Legal Officer, Secretary and Compliance Officer, and Alison Peters as Chief People Officer. Both Mr. Thompson and Ms. Peters bring deep expertise in building high-performing teams which will be essential to deliver success through the Company's next phase of growth. "We are thrilled to welcome both Rahsaan and Alison to the Zevra team as w
6/25/24 7:30:00 AM ET
$ZVRA
Biotechnology: Pharmaceutical Preparations
Health Care
Zevra Therapeutics' President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024
CELEBRATION, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane, Zevra's President and Chief Executive Officer, has issued a Letter to Stockholders providing a review of key accomplishments and outlook for 2024. Dear Stockholders, It is hard for me to believe that April 2024 marks six months since the start of my tenure as Zevra's President and Chief Executive Officer in October 2023. From that time, and even prior to my official start date, I began a listening tour, seeking feedback from many of Zevra's stakeholders – stockholders, investors, employees, patie
4/29/24 7:30:00 AM ET
$ZVRA
Biotechnology: Pharmaceutical Preparations
Health Care
Zevra Therapeutics Appoints Experienced Biopharma Executive Alvin Shih, MD, MBA, to the Board of Directors
CELEBRATION, Fla., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced the appointment of Alvin Shih, MD, MBA, to the Company's Board of Directors (Board) effective as of January 20, 2024. Dr. Shih has extensive experience in biotechnology leadership and rare disease therapeutics development and currently serves as President and CEO of Catamaran Bio, a biotechnology company developing cell therapies for multiple oncologic indications. "We are honored to welcome Dr. Shih to our Board as we advance our therapeutic portfolio of product candidates in multiple rare disease indications," said Tamar
1/23/24 7:30:00 AM ET
$ZVRA
Biotechnology: Pharmaceutical Preparations
Health Care

$ZVRA
Financials

Live finance-specific insights

Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024
CELEBRATION, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases, today announced it will report third quarter financial results and provide a corporate update on Tuesday, Nov. 12, 2024. The Company will issue a news release after the market closes and host a conference call/audio webcast at 4:30 p.m. ET that day. The corporate update will include recent progress with the commercial launches of MIPLYFFA™ and OLPRUVA® as well as the Company's clinical stage programs. A link to the audio webcast will be accessible on the "Events & Presentations"
10/31/24 7:30:00 AM ET
$ZVRA
Biotechnology: Pharmaceutical Preparations
Health Care
Zevra Therapeutics' MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C
MIPLYFFA is the first FDA-approved treatment for Niemann-Pick disease type C (NPC), an ultra-rare and progressive neurodegenerative disease MIPLYFFA is indicated for use in combination with miglustat for the treatment of neurological manifestations of NPC in adults and pediatric patients 2 years of age and older Zevra receives rare pediatric disease priority review voucher in conjunction with approval Company launches AmplifyAssist™ patient support program Conference call and webcast set for 8:00 a.m. EDT on Monday, Sept. 23, 2024 CELEBRATION, Fla., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage rare disease therap
9/20/24 12:08:07 PM ET
$ZVRA
Biotechnology: Pharmaceutical Preparations
Health Care
Zevra Therapeutics to Report Second Quarter 2024 Financial Results
CELEBRATION, Fla., July 30, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company) a rare disease therapeutics company, today announced that it will host a conference call and audio webcast on Tuesday, August 13, 2024, at 4:30 p.m. ET, to review its corporate and financial results for the second quarter of 2024. The link to the audio webcast will be accessible via the Investor Relations section of the Company's website, https://investors.zevra.com/. To join the meeting by conference call, use the dial-in information below. (800) 225-9448 (U.S.)+1 (203) 518- 9708 (International)Conference ID: ZVRAQ224 An archive of the webcast will be available for 90 da
7/30/24 8:38:30 AM ET
$ZVRA
Biotechnology: Pharmaceutical Preparations
Health Care

As of March 31, 2024, Zevra Therapeutics' Cash, Cash Equivalents, And Investments Were $52.7M, April 5, 2024, The Company Announced Refinancing Of Existing Debt With Up To $100M In Committed Capital, Expected To Provide Cash Runway Into 2026

Chat with this insight

Recent Analyst Ratings for $ZVRA

$ZVRA Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Watton Corey Michael bought $3,958 worth of shares (500 units at $7.92), increasing direct ownership by 50% to 1,500 units (SEC Form 4)

CFO & Treasurer Clifton R. Laduane bought $13,540 worth of shares (2,000 units at $6.77), increasing direct ownership by 12% to 18,469 units (SEC Form 4)

Director Anderson Thomas bought $68,065 worth of shares (10,000 units at $6.81), increasing direct ownership by 100% to 20,000 units (SEC Form 4)

$ZVRA Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Watton Corey Michael bought $3,958 worth of shares (500 units at $7.92), increasing direct ownership by 50% to 1,500 units (SEC Form 4)

CFO & Treasurer Clifton R. Laduane bought $13,540 worth of shares (2,000 units at $6.77), increasing direct ownership by 12% to 18,469 units (SEC Form 4)

Director Anderson Thomas bought $68,065 worth of shares (10,000 units at $6.81), increasing direct ownership by 100% to 20,000 units (SEC Form 4)

$ZVRA Press Releases

Fastest customizable press release news feed in the world

Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024

Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

NUCDF and Zevra Therapeutics Launch Check Ammonia Campaign to Highlight Critical Importance of Prompt, Accurate Blood Ammonia Testing for Diagnosing Urea Cycle Disorders

$ZVRA Market Insights

Live Market Insights

10 Health Care Stocks Whale Activity In Today's Session

Insiders Buying Zevra Therapeutics And 1 Other Stock

Insiders Buying Barnes & Noble Education And 2 Other Stocks

$ZVRA Leadership Updates

Live Leadership Updates

Zevra Therapeutics Expands Executive Leadership Team

Zevra Therapeutics' President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024

Zevra Therapeutics Appoints Experienced Biopharma Executive Alvin Shih, MD, MBA, to the Board of Directors

$ZVRA Financials

Live finance-specific insights

Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024

Zevra Therapeutics' MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C

Zevra Therapeutics to Report Second Quarter 2024 Financial Results

$ZVRA Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Guggenheim initiated coverage on Zevra Therapeutics with a new price target

JMP Securities initiated coverage on Zevra Therapeutics with a new price target

Maxim Group reiterated coverage on Zevra Therapeutics with a new price target

$ZVRA SEC Filings

Zevra Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

Zevra Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 8-K filed by Zevra Therapeutics Inc.

Recent Analyst Ratings for
$ZVRA

$ZVRA
Insider Purchases

$ZVRA
Insider Trading

$ZVRA
Press Releases

$ZVRA
Market Insights

$ZVRA
Leadership Updates

$ZVRA
Financials

$ZVRA
Analyst Ratings

$ZVRA
SEC Filings